The relationship between cost of treatment and cognitive deficit in schizophrenia

被引:0
|
作者
Amedu, Michael A. [1 ]
Sale, Shehu [2 ]
机构
[1] Fed Med Ctr, Dept Psychiat, Makurdi, Benue State, Nigeria
[2] Bayero Univ Kano, Dept Psychiat, Kano, Nigeria
关键词
Cognitive impairment; cost of treatment; Nigeria; schizophrenia; UNTREATED PSYCHOSIS; DURATION;
D O I
10.4103/njbcs.njbcs_9_20
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Schizophrenia is not only a complex and disabling illness, but also costly. Cognitive impairment is a major determinant of functional outcome of patients. Aims: To determine the relationship between the direct cost of treatment and the cognitive impairment in schizophrenia. Settings and Design: This is a longitudinal study at a tertiary mental health facility in northern Nigeria. Materials and Methods: This study involved 270 patients with schizophrenia aged 15-64 years. Instruments used included Schizophrenia Cognition Rating Scale (SCoRS), the Mini International Neuropsychiatric Interview PLUS and a modified cost of illness (COI) questionnaire. Statistical analysis used: All tests of statistics were carried out at 5% level of probability. Results: A total of 270 participated in this study with a male: female ratio of almost 1. The mean age of participants 33.04 years. Majority were unemployed (51.5%), single (45.6%) and of low socioeconomic class (88.5%). Lower SCoRS for stable patients was significantly associated with higher educational attainment, occupational and marital status, high socioeconomic status and absence of caregiver. SCoRS had a significant correlation with duration of untreated psychosis, COI, age at onset, duration of illness, length of caregiving and number of caregivers. Conclusion: Cognitive impairment experienced by patients with schizophrenia are numerous, not only by the suffering and limitations it imposes on them, but also the enormous cost and burden that comes with caregiving. Efforts geared toward early detection and presentation of schizophrenia patients, and subsidizing cost of drug by government will go a long way in reducing cognitive impairment among patients.
引用
收藏
页码:115 / 122
页数:8
相关论文
共 50 条
  • [31] Relationship between cognition and awareness of deficit in mild cognitive impairment
    Tremont, Geoffrey
    Alosco, Michael L.
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2011, 26 (03) : 299 - 306
  • [32] Relationship between cognitive functions and empathy in patients with neurocognitive deficit
    Markopoulos, A.
    Inserra, A.
    De Gregorio, D.
    Gobbi, G.
    EUROPEAN PSYCHIATRY, 2021, 64 : S416 - S416
  • [33] COGNITIVE DEFICIT IN SCHIZOPHRENIA AND ITS REMEDIATION
    Kucerova, Hana Prikrylova
    Fejfarova, Helena
    Navratilova, Petra
    Prikryl, Radovan
    SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 512 - 512
  • [34] DIRECT MEASUREMENT OF COGNITIVE DEFICIT IN SCHIZOPHRENIA
    WILLIAMS, HL
    GIESEKING, CF
    LUBIN, A
    AMERICAN PSYCHOLOGIST, 1958, 13 (07) : 358 - 358
  • [35] CONVERGING MODELS OF COGNITIVE DEFICIT IN SCHIZOPHRENIA
    KNIGHT, RA
    NEBRASKA SYMPOSIUM ON MOTIVATION, 1983, 31 : 93 - 156
  • [36] The neuromediator mechanisms of the cognitive deficit in schizophrenia
    Storozheva, Z. I.
    Kirenskaya, A. V.
    Proshin, A. T.
    NEUROCHEMICAL JOURNAL, 2015, 9 (03) : 186 - 200
  • [37] Cognitive Deficit in Schizophrenia: Specific or General?
    Gigi, Karny
    Davidson, Michael
    Reichenberg, Abraham
    Weiser, Mark
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S399 - S400
  • [38] The neuromediator mechanisms of the cognitive deficit in schizophrenia
    Z. I. Storozheva
    A. V. Kirenskaya
    A. T. Proshin
    Neurochemical Journal, 2015, 9 : 186 - 200
  • [39] DIRECT MEASUREMENT OF COGNITIVE DEFICIT IN SCHIZOPHRENIA
    LUBIN, A
    WILLIAMS, HL
    GIESEKING, CF
    JOURNAL OF CONSULTING PSYCHOLOGY, 1962, 26 (02): : 139 - &
  • [40] Neuropsychological remediation of cognitive deficit in schizophrenia
    Kucerova, H. Prikrylova
    Fejfarova, H.
    Navratilova, P.
    Prikryl, R.
    Ustohal, L.
    Hublova, V.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 235 - 235